RADIATION THERAPY TECHNIQUES AND COMBINATION TREATMENTS FOR SARCOMA
Professor Angela Hong, Director and
co-Chair of Scientific Advisory Committee,
Australia and New Zealand Sarcoma Association (ANZSA)
RESEARCHER PROFILE
Filmed Sydney, Australia | January 2025
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
She is also the Director and co-chair of the Scientific Advisory Committee for the Australia and New Zealand Sarcoma Association (ANZSA), a non-profit organisation aimed at enhancing treatment outcomes for sarcoma patients across Australia and New Zealand.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
After earning her medical degree from the University of Sydney, Angela undertook an 18-month fellowship in the United States to gain additional experience before returning to Sydney to start her formal training in radiation oncology. She later completed her PhD, concentrating on radiosensitivity in skin cancer sarcoma.
Professor Hong believes in a multidisciplinary approach to managing sarcoma, given its rarity and the complexities involved in diagnosis and treatment. She is actively involved in clinical research and recently contributed to an international trial led by Sarcoma Alliance for Research through Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The trial examined the advantages of including immunotherapy in the treatment regimen for high-risk soft tissue sarcoma, resulting in a notable improvement in two-year disease-free survival rates.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Liver cancer biomarkers, risk prediction & progression
Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.
-
Renal care & data linkage of Tasmanian kidney disease cases
Professor Matthew Jose is a Renal Physician & Head of the Renal Unit at the Royal Hobart Hospital, and Professor of Medicine for the University of Tasmania.
Winner of the 2021 Rural Science Award from the Australia and New Zealand Society of Nephrology, he has worked in regional, rural and remote Australian locations for nearly 20 years as a Renal Physician, including the Northern Territory.
